|Mr. Damien McDonald||CEO & Director||1.57M||N/A||1965|
|Ms. Keyna Pidcock Skeffington||Sr. VP, Gen. Counsel & Corp. Sec.||659.22k||N/A||1963|
|Mr. Alex Shvartsburg||Interim CFO and Corp. VP of Financial Planning, Analysis & International Region||N/A||N/A||N/A|
|Ms. Melissa Farina||VP of Investor Relations||N/A||N/A||N/A|
|Deanna Wilke||Director of Corp. Communications||N/A||N/A||N/A|
|Mr. Matthew Joseph Dodds III||Sr. VP of Corp. Devel.||N/A||N/A||N/A|
|Ms. Trui Hebbelinck||Chief HR Officer||N/A||N/A||1972|
|Mr. Pritpal Shinmar||Sr. VP of Global Market Access||N/A||N/A||1957|
|Dr. Bryan D. Olin||Sr. VP of Clinical, Quality Assurance & Regulatory Affairs||N/A||N/A||1967|
|Mr. Paul R. Buckman||Pres of North America & GM of Transcatheter Mitral Valve Replacement||N/A||N/A||1956|
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
LivaNova PLC’s ISS Governance QualityScore as of April 30, 2021 is 4. The pillar scores are Audit: 5; Board: 3; Shareholder Rights: 4; Compensation: 4.